← Russell 3000 cross-section

NRIX Nurix Therapeutics, Inc.

Trailing twelve months to 2026-05-31 · as filed 2026-07-09, not restated
Healthcare

Scale

Market cap
$2.8bn
Revenue TTM
$37m
Net income TTM
$-341m
Free cash flow
$-304m
Composite score
19.2
Sector rank
#1444

Valuation

P / E
EV / EBITDA
EV / sales
73.9
FCF yield
-10.93%
Earnings yield vs 10-yr
-16.99pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-928.4%
EBITDA margin
ROE
-84.8%
ROIC
-107.8%
Revenue growth
-58.4%

Insider activity, last 90 days

Net open-market
$-2.04m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Under the terms of the Roche Collaboration Agreement, we will receive an upfront cash payment of $700 million and will be eligible to receive development, regulatory and sales milestone payments for potential total payments of up to $2.3 billion, including the upfront payment. Also in July 2022, Sanofi elected to replace certain drug targets, and the substitution extended the research term of those targets by one year to 5.25 years and increased overall forecasted costs, which had an immaterial impact on revenue recognition. …Nurix Therapeutics, Inc., 10-Q, period ended 2026-05-31, filed 2026-07-09

Read the full passage →